Bozidar Jovicevic Podcasts

The Cost of a sales rep visit in the US is $300-$400 - what is the digital equivalent of one rep visit? What is the product adoption journey of HCPs nowadays and how can pharma companies respect it and achieve successful launches? What tools in the omnichannel toolbox does pharma have nowadays, and how should they plan to use them before launch? Ho…

What is Customer Experience (CX), and why are most pharma companies building CX teams? Why is CX powerful when it comes to HCP behavior change? What can pharma learn from Disney regarding content and use of data? To answer these questions, Bozidar is joined by Mark Makuch, SVP of Strategy at Havas Health CX. They cover: [ 04:31 ] - Customer experie…

What are the three critical components for value creation in the life cycle of a product? What does value creation mean in pharma launches? What is the difference between must-haves and innovative treatment value creators? How do digital and agile methodologies help pharma organizations streamline and improve their go-to-market strategies? To answe…

- Just how outdated are the FDA regulations? - What is the new normal when it comes to product launches, regulations, and advertising? - How can you creatively market pharma products without breaking the rules? To answer these questions Bozidar is joined by Dale Cooke, President of PhillyCooke Consulting, a company that focuses on ensuring that rel…

What is the Pharma-Startup Gap and how to bridge it? What are the three biggest mistakes that digital health startups make when approaching pharma companies? Are digital health founders coming from the pharma industry, or are they newcomers? What is the number one challenge that pharma faces when engaging with startups? Can startups strike a seven-…

How can pharma tap into patients' concerns when preparing a product launch? How can pharma produce content that will engage patients? How can the search listening methodology help pharma companies work more effectively with patient advocacy groups? To answer these questions, Bozidar is joined by Julia Walsh, CEO of Brand Medicine International. The…

How long should videos be to drive HCP behavior change? Why don't peer-to-peer videos need to be high-production and costly? Owned HCP audience versus rented HCP audience - how can pharma benefit from both? To answer these questions and many more, Bozidar is joined by Chris Savage, Co-founder, and CEO of Wistia. They cover: [ 01:18 ] - If you are a…

Why will new launches not be able to make up for the patent cliff? What is a “hyper-focused launch,” and what are the key ways to execute it? What can big pharma learn from how Google launches products? To answer these questions and many others, Bozidar is joined by Indraneel Mukherjee, Senior Principal, Commercial Strategy at IQVIA Strategy Consul…

4 Es of video: Why is video the future business driver? Why do customers today prefer to see a video than talk to someone in-person? How can regulated industries get away from the “but we are regulated” excuse and use more video in their marketing? Why is YouTube NOT the right place for life-science companies to host and stream video content? Is th…

How are first-in-class launches distinct from me-too launches? Why is it harder to access HCPs and launch products successfully? What are the opportunities for 1st-time launchers to have successful launches despite reduced access to HCPs? Will pharma encourage or discourage peer-to-peer scientific exchange online? To answer these questions, Bozidar…

Why has the number of 1st-time launchers increased threefold over the last 10 years? Why do 60%+ of 1st-time launches fail, and how do they compare to big pharma launches? What can 1st-time launchers learn from Mike Tyson about strategy and adapting to the circumstances? To answer these questions, Bozidar is joined by Rohit Sood, Executive Vice Pre…

What are the three most common forms of P2P programs? Why are short clinical pearls coming from a trusted voice, delivered in a personalized way, the future of HCP engagement? What is one feature that HCPs request for virtual, real-time, and on-demand P2P engagement programs? To answer these questions, Bozidar is joined by Andrew Willmer, EVP of St…

What is the best way to orchestrate personalized digital experiences for HCPs and patients? What is the “data flywheel,” and how can it give pharma companies a competitive advantage? Who is better suited for the digital-first future, large pharma companies or smaller, first-time launchers? Why is starting with the user imperative for the digital-fi…

In this episode of Pharma Launch Secrets, Bozidar is joined by Bharti Rai, the former VP of Commercial Acceleration Commercial Operations, Insights, Analytics, Data & Digital at Novartis, and now the SVP and GM of Health Insights, Products, and Solutions at CVS. They discuss the role of data analytics in customer personalization, driving business, …

In this episode of Pharma Launch Secrets, Bozidar is joined by Trevor Landry, Senior Vice President - Commercial Lead at Syneos Health. They discuss the successful launches behind Ozempic and Rybelsus, why companies should set up omnichannel promotional efforts for their pharma products, and the importance of engaging digitally with your customers.…

Apps and emails have been shown to be just as effective as social media outlets in distributing content. Data can be collected, challenged, and evaluated without depending on a third party since the marketer's function is getting more specialized, and data is being kept in-house. Content creation will migrate away from large-scale content factories…

In this episode of Pharma Launch Secrets, Bozidar is joined by Indraneel Mukherjee, an Associate Partner at ZS Associates. He discusses the biggest changes facing pharma companies launching products in the US pre-COVID and post-COVID. They delved into the concept of "blockbuster products" and how this concept is growing obsolete. He also talks abou…

Meg discusses how COVID-19 was a transformational moment for the pharmaceutical industry, and how it has forced companies to re-examine, at multiple levels, the way they do business. Meg and Bozidar delve into innovation in the biotech industry, and how businesses will find new methods to connect and rely on solid partnerships, by developing meanin…

In this episode of Pharma Launch Secrets, Bozidar is joined by Brendan Gallagher, Chief Connected Health Officer at Publicis Health. They discuss the impact of the pandemic on pharma and biotech companies and how COVID-19 is driving them to evolve their product launch strategy. Brendan analyzes how pharma companies can balance speed and competitive…

In this episode of Pharma Launch Secrets, Bozidar is joined by Matthew Goodman, Medical Director, and Principal at LUCENT biopharma. They discuss the importance of digital innovation as a key driver of launch success and how it’s transforming the product launch paradigm in an omnichannel world. They discuss the need to bridge the gap between sales …

The conventional sales channels utilized by pharma are vanishing. The question that remains... what are they going to do now? Pharma needs to discover new approaches of promoting drugs and appealing to physicians, and in the long run aim to create a brand-new channel through which they will be able to influence them, says Bozidar Jovicevic, CEO at …

Welcome to Pharma Launch Secrets, a podcast by Evermed. We host honest, direct, actionable conversations with world-leading pharma launch experts that will help you stay up to date with trends and strategies to help you launch your product successfully. This podcast is brought to you by Evermed. Evermed licenses software to pharma companies so they…